Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583488 · ClinicalTrials.gov registry record · Phase 1
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04583488: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT04583488 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04583488, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).
Interventions
- DRUG Intraperitoneal docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583488
The ClinicalTrials.gov registry entry for NCT04583488 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intraperitoneal docetaxel is the first listed.
NCT04583488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583488 about?
NCT04583488 is a clinical study titled "Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis". This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).
What is the current status of trial NCT04583488?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-11-01. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT04583488?
The interventions under investigation include: Intraperitoneal docetaxel (DRUG).
Who is sponsoring clinical trial NCT04583488?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.